Rhegmatogenous Retinal Detachment (RRD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Rhegmatogenous Retinal Detachment (RRD) Market Outlook

Thelansis’s “Rhegmatogenous Retinal Detachment (RRD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Rhegmatogenous Retinal Detachment (RRD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Rhegmatogenous Retinal Detachment (RRD) Overview

Rhegmatogenous retinal detachment (RRD) is a type of retinal detachment characterized by subretinal fluid between the neurosensory retina and the underlying retinal pigment epithelium. RRD typically occurs when a full-thickness defect in the neurosensory retina allows fluid to enter the subretinal space and separate the retina from the retinal pigment epithelium. The most common cause of RRD is the degeneration of the vitreous body, a gel-like substance that helps maintain the eye's shape. The vitreous body liquefies over time, creating a potential space for fluid to accumulate. RRD is more common in myopic individuals and those who have previously undergone cataract surgery. Patients with RRD may experience light flashes, floaters, or a visual "curtain" that obscures part of the visual field. The visual acuity can range from excellent to poor, depending on whether the macula remains attached. The presence of an afferent pupillary defect may indicate a large area of detachment. Various factors, including the liquefaction of the vitreous body, the presence of retinal breaks, and the adhesion mechanisms between the neurosensory retina and the retinal pigment epithelium, influence the development of RRD. The risk of RRD also varies based on factors such as gender, ethnicity, age, axial length, and prior eye surgery.

• Patients who have undergone cataract surgery are at an increased risk for developing RRD, with an estimated one in five in the UK being pseudophakic. The risk of developing RRD after phacoemulsification is estimated to be between 0.5% to 0.6%.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: